Key Points
- Artivion SVP Andrew Green sold 11,480 shares at an average price of $24.97, generating $286,655.60 and reducing his stake by 22.23% to 40,160 shares.
- Artivion shares opened at $25.13, while the company’s latest quarterly results exceeded expectations with $0.13 in EPS and $125.76 million in revenue versus the $119.99 million analyst estimate.
- Analyst sentiment remains broadly positive, with seven Buy ratings and one Sell rating, producing a “Moderate Buy” consensus and an average price target of $44.83; institutional investors own 86.37% of the stock.
Artivion, Inc. (NYSE:AORT - Get Free Report) SVP Andrew Green sold 11,480 shares of the stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $24.97, for a total transaction of $286,655.60. Following the transaction, the senior vice president owned 40,160 shares in the company, valued at approximately $1,002,795.20. The trade was a 22.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Artivion Stock Up 1.9%
Shares of AORT opened at $25.13 on Friday. Artivion, Inc. has a 12 month low of $19.16 and a 12 month high of $48.25. The firm's 50 day moving average is $26.27 and its 200-day moving average is $28.78. The stock has a market capitalization of $1.23 billion, a PE ratio of -358.92 and a beta of 1.25. The company has a current ratio of 3.47, a quick ratio of 2.51 and a debt-to-equity ratio of 0.82.
Artivion (NYSE:AORT - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter. The business had revenue of $125.76 million during the quarter, compared to analysts' expectations of $119.99 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. Equities research analysts forecast that Artivion, Inc. will post 0.45 EPS for the current year.
Analyst Ratings Changes
A number of analysts have recently weighed in on the company. Stifel Nicolaus set a $45.00 target price on Artivion in a research report on Monday, June 1st. Wall Street Zen cut Artivion from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Weiss Ratings downgraded Artivion from a "sell (d+)" rating to a "sell (d-)" rating in a research note on Tuesday, August 11th. Needham & Company LLC reaffirmed a "buy" rating and issued a $44.00 price target on shares of Artivion in a research note on Monday, July 20th. Finally, Canaccord Genuity Group upped their price objective on shares of Artivion from $39.00 to $40.00 and gave the stock a "buy" rating in a research report on Tuesday, August 18th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Artivion currently has an average rating of "Moderate Buy" and a consensus target price of $44.83.
Get Our Latest Stock Report on Artivion
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd bought a new stake in Artivion during the third quarter worth $27,000. Rockefeller Capital Management L.P. increased its stake in shares of Artivion by 150.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company's stock valued at $30,000 after purchasing an additional 399 shares during the last quarter. Larson Financial Group LLC increased its stake in shares of Artivion by 148.5% in the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company's stock valued at $43,000 after purchasing an additional 563 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of Artivion by 47.7% during the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company's stock worth $52,000 after buying an additional 538 shares in the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of Artivion during the 4th quarter worth $79,000. 86.37% of the stock is currently owned by institutional investors and hedge funds.
Artivion Company Profile
(
Get Free Report)
Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.
Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
